UEGweek 2025

IL-23 inhibition: sc is nice, oral is better ?!

A new oral α4β7 integrin inhibitor - more questions…

New molecules in moderate to severe UC: obefazimod &…

New rumours about small molecules

Are JAK inhibitors better than their reputation?

If it helps, can we stop it? Drug withdrawel in IBD

Pregnancy and family planning in IBD

Timing is everything - surgical intervention in CD

Modifying the diet does have an impact on IBD risk!

Complete disease clearence - the quest for the optimal…

Do biologics need an iv induction?

JAKis may be safer than you probably think they are!

Efficacy of sc induction with guselkumab therapy in UC

T2T in UC - first piece of restrospective evidence

Effektivität der s.c. Induktion mit Guselkumab bei UC

Braucht es eine i.v. Induktion bei Biologika?

T2T nella CU – prime evidenze retrospettive

Efficacy of Guselkumab in CD patients who lost response…

Can we stop Adalimumab in CD patients achieving…

Therapy sequence: guselkumab is possible after…

10 years after the LIR!C trial – the update of the…

Is it possible to stop anti-TNF treatment in early CD…

Efficacy of guselkumab in patients with inadequate…

Patients with early Crohn’s disease on adalimumab: can…

Perianal CD - it's associated with low infliximab…

To stop or not to stop? That is the question (in…

Early treatment with adalimumab does not allow for…

Peut-on arrêter un anti-TNF dans la maladie de Crohn…

Czy przerywać skuteczne leczenie u pacjentów z chorobą…

Ασθενείς με πρόσφατη έναρξη νόσου του Crohn σε…

10 lat po badaniu LIR!C – aktualizacja danych o…

Therapiesequenz: Guselkumab nach Ustekinumab-Versagen…

Efficacia di Gusekumab in pazienti affetti da malattia…

הזרקת תאים לפיסטולה במחלת קרוהן- הסיפור שאינו נגמר?

CAR-T cells in refractory UC – a new option for the…

Go for oral anti-α4β7!

IL-23 blockade now also oral

B-cell depletion in refractory ulcerative colitis –…

Oral mufemilast, a PDE4 inhibitor, for moderate to…

Icotrokina - a new oral drug for blocking IL-23

Les cellules CAR-T dans la RCH réfractaire – une…

Obefazimod - Une nouvelle classe thérapeutique pour la…

IL-23 Blockade jetzt auch oral

Mufemilast, αναστολέας της PDE4, για θεραπεία από του…

B-Zell-Depletion bei refraktärer Colitis Ulcerosa -…

Obefazimod in moderate to severe UC

Short-term (8 weeks) efficacy & safety of obefazimod in…

Histo-endoscopic endpoint in long-term extension of…

Etrasimod in mild to moderate UC

Real-world short-term efficacy and safety of…

Long term persistence of ustekinumab in Real-Life…

Μακροχρόνια αποτελεσματικότητα της ουστεκινουμάμπης σε…

Obefazimod nella colite ulcerosa da moderata a grave

Efectividad y seguridad en vida real a corto plazo de…

Obefazimod-Induktionstherapie ist effektiv und gut…

Etrasimod nella colite ulcerosa da lieve a moderata

Eficacia y seguridad a corto plazo (8 semanas) de…

Endlich Zeit das automatisierte 5-ASA Weiterführen zu…

Risankizumab in Crohn’s disease - real-world data…

Guselkumab sc in crohn’s disease with inadequate…

Ustékinumab dans la maladie de Crohn ano-périnéale

Guselkumab sc en enfermedad de crohn con respuesta…

Sigmoid volvulus: an old problem, still waiting for…

When nanoparticles calm down celiac-specific T-cells

Steroid-sparing effect of upfront Vedolizumab in…

Selection criteria for randomized clinical trials in…

Real-life vs clinical trials IBD patients access to…

Reassuring safety signals of JAKis in pregnant IBD…

Looking for the black sheep pathways

IUS as a patient- and environmental-friendly tool in…

IBD outcome in a large national cohort from spain

Let's go green! ecological effect of patient monitoring

Vedolizumab - another option for JAKi-induced…

New insights from the GEM trail

AI-endoscopy ready - is it a game changer?

Eosinophilic esophagitis doesn’t seem to increase the…

Wenn Nanopartikel zöliakiespezifische T-Zellen…

Critères de sélection des essais cliniques randomisés…

Segnali si sicurezza rassicuranti in donne affette da…

Auf der Suche nach den schwarzen Pathway-Schafen

JAK-Inhibitoren und Schwangerschaft bei CED

Πρόσβαση σε προχωρημένες θεραπείες καθημερινών ασθενών…

Vedolizumab - eine zusätzliche Therapieoption bei…

Eosinophile Ösophagitis ist kein Risikofaktor für ein…

Co ma wspólnego USG jelit w IBD z ekologią?

פתלת הפרשדון....בעיה מוכרת שעדין מחכה לפתרון

Verso il verde! L’impatto ecologico del monitoraggio…